Format

Send to

Choose Destination
Sci Transl Med. 2010 Jun 30;2(38):38ra47. doi: 10.1126/scitranslmed.3000611.

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Author information

1
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0310 Oslo, Norway.
2
Division of Pathology, Oslo University Hospital Radiumhospitalet, 0310 Oslo, Norway.
3
Insitute for Clinical Medicine, Faculty of Medicine, University of Oslo.
4
Department of Breast and Endocrine Surgery, Division of Surgery and Cancer, Oslo University Hospital, 0450 Oslo, Norway.
5
Biomedical Research Group, Department of Informatics, University of Oslo, P.O. Box 1080 Blindern, 0316 Oslo, Norway.
6
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
7
Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, SE-171 76 Stockholm, Sweden.
8
Department of Oncology, Division of Surgery and Cancer, Oslo University Hospital Radiumhospitalet, 0310 Oslo, Norway.
9
Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Li Ka-Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
10
UCL Cancer Institute, University College London, WC1E 6BT, UK.
11
Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
12
Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.
13
Cambridge Breast Unit, Addenbrookes Hospital and Cambridge NIHR Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, UK.
#
Contributed equally

Abstract

Distinct molecular subtypes of breast carcinomas have been identified, but translation into clinical use has been limited. We have developed two platform-independent algorithms to explore genomic architectural distortion using array comparative genomic hybridization data to measure (i) whole-arm gains and losses [whole-arm aberration index (WAAI)] and (ii) complex rearrangements [complex arm aberration index (CAAI)]. By applying CAAI and WAAI to data from 595 breast cancer patients, we were able to separate the cases into eight subgroups with different distributions of genomic distortion. Within each subgroup data from expression analyses, sequencing and ploidy indicated that progression occurs along separate paths into more complex genotypes. Histological grade had prognostic impact only in the luminal-related groups, whereas the complexity identified by CAAI had an overall independent prognostic power. This study emphasizes the relation among structural genomic alterations, molecular subtype, and clinical behavior and shows that objective score of genomic complexity (CAAI) is an independent prognostic marker in breast cancer.

Comment in

PMID:
20592421
PMCID:
PMC3972440
DOI:
10.1126/scitranslmed.3000611
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center